List of Osmolex Er drug patents
Osmolex Er is owned by Adamas Pharma.
Osmolex Er contains Amantadine Hydrochloride.
Osmolex Er has a total of 18 drug patents out of which 0 drug patents have expired.
Osmolex Er was authorised for market use on 16 February, 2018.
Osmolex Er is available in tablet, extended release;oral dosage forms.
Osmolex Er can be used as treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease, treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of parkinson's disease, a process for treating a patient suffering from parkinson's syndrome and in need of treatment, treatment of drug-induced extrapyramidal reaction in adult patients, treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of drug-induced extrapyramidal reaction in adult patients.
The generics of Osmolex Er are possible to be released after 15 February, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895618 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8796337 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895614 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8987333 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8889740 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US9072697 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895616 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8895615 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Nov, 2025
(2 years from now) | |
| US8574626 | ADAMAS PHARMA | Osmotic device containing amantadine and an osmotic salt |
Nov, 2025
(2 years from now) | |
| US8389578 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Jan, 2028
(4 years from now) | |
| US8252331 | ADAMAS PHARMA | Osmotic device containing amantadine and an osmotic salt |
Mar, 2030
(6 years from now) | |
| US10512617 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10213393 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500172 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500171 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10213394 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
| US10500170 | ADAMAS PHARMA | Composition and method for treating neurological disease |
Feb, 2038
(14 years from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of parkinson's disease; Treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of drug-induced extrapyramidal reaction in adult patients; A ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic